Anthem Biosciences IPO: Key Highlights4 min read

Anthem Biosciences IPO: Key Highlights4 min read

Anthem Biosciences Limited is launching its Initial Public Offering (IPO). Here’s a quick snapshot of the key details:

The promoters of ABL are:

• Ajay Bhardwaj
• Ganesh Sambasivam
• K. Ravindra Chandrappa
• Ishaan Bhardwaj

This IPO is a complete Offer for Sale, which means proceeds will go to the existing shareholders and not to the company.

About the company

Anthem Biosciences Limited (ABL) is an innovation-led, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO). It provides fully integrated services spanning:

• Drug discovery
• Development
• Commercial manufacturing

Key offerings include capabilities for New Chemical Entities (NCEs) and New Biological Entities (NBEs) for both emerging biotech and global pharmaceutical giants.

Core Modalities & Manufacturing Capabilities

• Modalities: RNAi, ADCs, peptides, lipids, oligonucleotides
• Manufacturing: Custom synthesis, flow chemistry, fermentation, biotransformation

Objects of the issue

• To carry out the Offer for Sale
• To achieve the benefits of listing on stock exchanges

Financials of the company

Basis of Offer price

1. The company offers a comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and we are the fastest growing Indian CRDMO.
2. The company has innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
3. Differentiated business model catering to the needs of small pharmaceutical and emerging biotech companies, from discovery to commercial manufacturing.
4. Long-standing relationships with a large, diversified and loyal customer base.
5. Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products, probiotics, enzymes, nutritional actives, vitamin analogues and biosimilars.
6. Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.

Risk Factors

• The company’s business depends on the demand for our CRDMO services, which contributed to 81.65% of our revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers’ business or the industries in which they operate may have a material adverse effect on its business.
• Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of its total number of Projects in Fiscal 2025. The company’s business may be adversely affected by a failure in early phase developmental Projects or a failure to develop or manufacture commercially viable drugs, including for reasons that are not within its control
• The company’s financial performance is dependent on the success of the molecules it manufactures, any failure to deliver a commercial molecule is a risk factor.
• The company needs to keep pace with rapid change in technology. This requires continuous investments. Any failure to input required investment would be a major risk factor.

Investment Rationale

• According to the F&S Report, the global pharmaceutical industry is projected to grow to U.S. $ 2,076.0 billion by 2029, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models.
• According to the F&S Report, the Indian CRDMO industry is expected to grow at a CAGR of 13.4% from 2024 to 2029 to reach an estimated value of U.S.$ 15.4 billion.
• Development of “Make in India” programs for pharmaceuticals with PLI scheme.
• Schemes targeted specifically to promote the development of Bulk Drug Parks are expected to boost the manufacturing of drug intermediates and API.
• Favorable FDI Policies: The Indian government allows up to 100% FDI in the pharmaceutical
  sector, allowing the investor to enjoy the sole rights to its establishment.
• Cumulative FDI in the Indian pharmaceutical sector grew at a CAGR of 27.2% from USD 18 billion in FY20196 to USD 60 billion in FY2024 (As of September 2024)7.
• Strong Development and Manufacturing base: The Indian pharma industry is highly developed, with approximately 3,000 drug companies, 10,500 manufacturing units, and the largest number of US FDA-approved plants (March 31, 2025) outside of the US as of 2025.
• Lower manufacturing costs: India provides substantial cost advantages in terms of labor and operational expenses compared to the US and Western markets.

by Manish Shah (SEBI Registration No: INA000016180)

Disclaimer: Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, enlistment with BSE and certification from NISM in no way guarantee performance of the Research Analyst or provide any assurance of returns to investors. Paytm Money Ltd SEBI Reg No. Broking – INZ000240532, Depository Participant – IN – DP – 416 – 2019, Depository Participant Number: CDSL – 12088800, NSE (90165), BSE (6707), SEBI reg No. Research Analyst – INH000020086. Regd Office: 136, 1st Floor, Devika Tower, Nehru Place, Delhi – 110019. For complete details, please visit ; https://www.paytmmoney.com